Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Trazimera 420mg pdr for concentrate for inf vials
0801050ADBGABAE
|
Trazimera | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trazodone 100mg/5ml oral liquid
0403010X0AAAIAI
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Trazodone 10mg/5ml oral liquid
0403010X0AAAKAK
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Trazodone 150mg modified-release tablets
0403010X0AAAEAE
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Trazodone 150mg/5ml oral liquid
0403010X0AAALAL
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Trazodone 250mg/5ml oral liquid
0403010X0AAAHAH
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Trazodone 25mg/5ml oral liquid
0403010X0AAAJAJ
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Trazodone 75mg/5ml oral liquid
0403010X0AAAMAM
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | No data available |
|
Treathay 120mg tablets
0304010E0BDAAAA
|
Treathay | Fexofenadine hydrochloride | Respiratory System | No data available |
|
Trecondi 1g powder for solution for infusion
0801010Z0BBAAAD
|
Trecondi | Treosulfan | Malignant Disease and Immunosuppression | No data available |
|
Trecondi 5g powder for solution for infusion
0801010Z0BBABAB
|
Trecondi | Treosulfan | Malignant Disease and Immunosuppression | No data available |
|
Tredaptive 1000mg/20mg modified-release tablets
0212000AEBBAAAA
|
Tredaptive | Nicotinic acid/laropiprant | Cardiovascular System | No data available |
|
Tremfya 100mg/1ml solution for injection pre-filled pens
1305030F0BBABAB
|
Tremfya | Guselkumab | Skin | No data available |
|
Tremfya 100mg/1ml solution for injection pre-filled syringes
1305030F0BBAAAA
|
Tremfya | Guselkumab | Skin | No data available |
|
Treosulfan 1g powder for solution for injection vials
0801010Z0AAADAD
|
Treosulfan | Treosulfan | Malignant Disease and Immunosuppression | No data available |
|
Treosulfan 250mg capsules
0801010Z0AAACAC
|
Treosulfan | Treosulfan | Malignant Disease and Immunosuppression | No data available |
|
Treosulfan 5g powder for solution for injection vials
0801010Z0AAABAB
|
Treosulfan | Treosulfan | Malignant Disease and Immunosuppression | No data available |
|
Tretinoin 0.025% lotion
1306010V0AAACAC
|
Tretinoin (Acne) | Tretinoin | Skin | No data available |
|
Tretinoin 0.1% gel
1306010V0AAAPAP
|
Tretinoin (Acne) | Tretinoin | Skin | No data available |
|
Tri-Adcortyl cream
1304000Z0BGABCE
|
Tri-Adcortyl (Topical) | Triamcinolone acetonide | Skin | No data available |
|
Tri-Adcortyl ointment
1304000Z0BGACCJ
|
Tri-Adcortyl (Topical) | Triamcinolone acetonide | Skin | No data available |
|
Tri-Adcortyl Otic ointment
1201010Z0BDAAAC
|
Tri-Adcortyl (Ear) | Triamcinolone acetonide | Ear, Nose and Oropharynx | No data available |
|
Tri-Form drainable night drainage bag
22601006060
|
Tri-Form drainable night drainage bag | Night Drainage Bags | Incontinence Appliances | No data available |
|
Tri-iodothyronine 20microgram inj ampoules
0602010M0BGAAAB
|
Tri-iodothyronine | Liothyronine sodium | Endocrine System | No data available |
|
Tri-Luma cream
131500000BBNAA0
|
Proprietary compound preparation BNF 1315000 | Other miscellaneous topical preparations | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.